Saccharomyces boulardii CNCM I-745 in different clinical conditions
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Saccharomyces boulardii is a well-known probiotic worldwide, and there are numerous studies including experimental and clinical trials in children and adults by the use of S. boulardii. AREAS COVERED: The objective of the present report is to provide an update on the evidence for the efficacy of S. boulardii CNCM I-745 in different clinical conditions. Saccharomyces boulardii is one of the best-studied probiotics in acute gastroenteritis (AGE) and is shown to be safe and to reduce the duration of diarrhea and hospitalization by about 1 day. Saccharomyces boulardii is one of the recommended probiotics for AGE in children by European Society of Paediatric Infectious Diseases and European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Saccharomyces boulardii is also a recommended probiotic for the prevention of antibiotic-associated diarrhea (AAD), and a recent study showed promising results for the treatment of AAD in children. There is insufficient evidence to recommend the long-term use of S. boulardii in patients with irritable bowel syndrome. Although some clinical studies showed positive effects of S. boulardii on inflammation, there is no clinical evidence that S. boulardii is useful in inflammatory bowel disease. Saccharomyces boulardii could be used in patients needing Helicobacter pylori eradication because the S. boulardii improves compliance, decreases the side effects and moderately increases the eradication rate. There are new promising results (improving feeding tolerance, shorten the course of hyperbilirubinemia), but we do still not recommend the routine use of S. boulardii in newborns. EXPERT OPINION: Saccharomyces boulardii CNCM I-745 is a good example for the statement that each probiotic needs to be taxonomically characterized and its efficacy and safety should be documented individually in different clinical settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guarino, A., Ashkenazi, S., Gendrel, D., Lo Vecchio, A., Shamir, R., & Szajewska, H. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000375 · Cited by 935
Review article: yeast as probiotics – Saccharomyces boulardii
CZERUCKA, D., PICHE, T., & RAMPAL, P. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03442.x · Cited by 587
World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics October 2011
Guarner, F., Khan, A. G., Garisch, J., Eliakim, R., Gangl, A., Thomson, A., Krabshuis, J., Lemair, T., Kaufmann, P., de Paula, J. A., et al. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182549092 · Cited by 418
Kelesidis, T., & Pothoulakis, C. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11428502 · Cited by 377 · cited 27×
“Saccharomyces boulardii also reduced the risk of AAD, which is caused either by Clostridium difficile or of unknown etiology compared with placebo [34].”
BackgroundInfluentialCremonini, F., Caro, S., Covino, M., Armuzzi, A., Gabrielli, M., Santarelli, L., Nista, E. C., Cammarota, G., Gasbarrini, G., & Gasbarrini, A. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.07063.x · Cited by 341
Choi, C. H., Jo, S. Y., Park, H. J., Chang, S. K., Byeon, J.-S., & Myung, S.-J. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318204593e · Cited by 144
Cindoruk, M., Erkan, G., Karakan, T., Dursun, A., & Unal, S. (2007) · Helicobacter · doi:10.1111/j.1523-5378.2007.00516.x · Cited by 135
Riaz, M., Alam, S., Malik, A., & Ali, S. M. (2012) · The Indian Journal of Pediatrics · doi:10.1007/s12098-011-0573-z · Cited by 43 · cited 2×
“boulardii in different settings in developing and developed countries [6-23].”
Background
Cited by
Saccharomyces boulardii: What Makes It Tick as Successful Probiotic?
Pais, P., Almeida, V., Yılmaz, M., & Teixeira, M. C. (2020) · Journal of Fungi · doi:10.3390/jof6020078 · Cited by 327
From yaks to yogurt: the history, development, and current use of probiotics
McFarland, L. V. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ054 · Cited by 248
“ate data may be pooled and analyzed [41, 42].”
Update of probiotics in human world: A nonstop source of benefactions till the end of time
Zommiti, M., Feuilloley, M. G. J., & Connil, N. (2020) · Microorganisms · doi:10.3390/microorganisms8121907 · Cited by 225
Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections
Czerucka, D., & Rampal, P. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i18.2188 · Cited by 116
McFarland, L. (2015) · Antibiotics · doi:10.3390/antibiotics4020160 · Cited by 109
“The most current strain designation for S. boulardii is CNCM I-745, the registration number at the Pasteur Institute [42], but older studies also refer to this strain as S. boulardii lyo, or S. boulardii, with no strain designation or by the brand name “Florastor”.”
Background
Metadata
- Authors
- Dinleyici, E. C., Kara, A., Ozen, M., & Vandenplas, Y.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2014-07-04
- Volume
- 14
- Issue
- 11
- Pages
- 1593-1609
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2018480278
- Cited by
- 49
- References
- 8
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Saccharomyces boulardii CNCM I-745 in different clinical conditions. https://app.cochat.ai/papers/10.1517/14712598.2014.937419
- The paper
- Dinleyici, E. C., Kara, A., Ozen, M., & Vandenplas, Y. (2014). Saccharomyces boulardii CNCM I-745 in different clinical conditions. Expert Opinion on Biological Therapy. https://doi.org/10.1517/14712598.2014.937419
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.